Genmab A/S (OTCMKTS:GNMSF – Get Free Report) was up 29.6% on Thursday. The company traded as high as $569.70 and last traded at $569.06. Approximately 39 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 2,784 shares. The stock had previously closed at $439.05.
Genmab A/S Price Performance
The company has a market capitalization of $34.71 billion, a PE ratio of 39.75 and a beta of 0.75. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The stock has a 50 day moving average price of $370.26 and a two-hundred day moving average price of $305.05.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Featured Stories
- Five stocks we like better than Genmab A/S
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
